PCT & Hormonal

PCT & Hormonal research, in depth

These compounds are well-characterized pharmaceuticals with decades of clinical data. They restore or modulate endogenous hormone production, and most are studied here in an off-label research context.

Two drug classes, one regulatory job

This category is built mainly from two established drug classes. Selective estrogen receptor modulators (SERMs) — Tamoxifen, Clomiphene, Enclomiphene, Raloxifene, Toremifene — block estrogen feedback at the hypothalamus and pituitary, prompting the gonadal axis to resume signalling. Aromatase inhibitors — Anastrozole, Letrozole, Exemestane — instead reduce the conversion of androgens to estrogen. Both classes are long-approved medicines with substantial trial histories, which sets them sharply apart from the more experimental compounds elsewhere on the site.

The research interest tracked here is their use in restoring endogenous hormone production — for example after suppression by exogenous androgens, the context the category name ("post-cycle therapy") refers to.

Where the research stands

This is the strongest evidence category on the site, and for a simple reason: these are real, approved pharmaceuticals. Their pharmacology, dosing and safety profiles are documented across decades of clinical use and regulatory review. What is less formally studied is the specific off-label application tracked here — hormonal recovery and modulation outside the approved indications — which relies more on clinical experience and smaller studies than on dedicated large trials. The honest reading: the drugs themselves are well-characterised; the particular use case is the part to research carefully, ideally from primary clinical literature.

Notable compounds in this category

Among the SERMs, Enclomiphene — the trans-isomer of clomiphene — is the one under active investigation as a standalone treatment, while Tamoxifen and Clomiphene are the long-established reference compounds. Among aromatase inhibitors, Anastrozole is the most familiar. SERMs and aromatase inhibitors are not interchangeable: one blocks the estrogen signal, the other lowers estrogen production.

What to keep in mind

• Unlike most of the site, these are approved drugs — their core clinical data is mature and well-documented.
• SERMs and aromatase inhibitors act through different mechanisms and are not interchangeable.
• The off-label recovery use is less formally studied than the drugs' approved indications.
• These compounds meaningfully affect hormonal systems — the primary clinical literature is the right reference.